Overview

A Study to Evaluate the Effect of KarXT on Urological Safety

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Phase:
PHASE4
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
trospium chloride
xanomeline